Correction to: Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy

HomeCirculationVol. 146, No. 15Correction to: Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection to: Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy Originally published10 Oct 2022https://doi.org/10.1161/CIR.0000000000001108Circulation. 2022;146:e224This article corrects the followingProteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-CardiomyopathyIn the article by Dhingra et al, “Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy,” which appeared in the September 20, 2022, issue of the journal (Circulation. 2022;146:934–954. doi: 10.1161/CIRCULATIONAHA.121.058411), a correction is needed.One author’s name and degree in the byline was incorrect. The correct name is Keshav Narayan Alagarsamy, M.Eng.This article has been corrected and is available at https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.058411.FootnotesCirculation is available at www.ahajournals.org/journal/circ Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesProteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-CardiomyopathyRimpy Dhingra, et al. Circulation. 2022;146:934-954 October 11, 2022Vol 146, Issue 15 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIR.0000000000001108PMID: 36214137 Originally publishedOctober 10, 2022 PDF download Advertisement